AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03752008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor Play (OP)
Description: This intervention focused on promoting outdoor time in preschoolers as a means to increasing their PA, using both child initiated and teacher-led activities. The training and materials were designed to emphasize the teacher's own connection with nature, the benefits of outdoor time for children and adults, and problem solving around barriers encountered. Teachers at participating centers attended one 3-hour workshop (delivered at the childcare center) that focused on having participants recognize their own connection with the natural world and how to transmit that to the next generation. Teachers were given hats and gloves for themselves, a set of rain jackets and boots for the preschoolers, and ideas on what children could do outdoors to be active.
Study NCT04754750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega]
Study NCT04754750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA]
Study NCT01721057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01721057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT01721057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cDMARD
Description: Conventional disease-modifying anti-rheumatic drug as a background therapy
Study NCT01721057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cDMARD
Description: Conventional disease-modifying anti-rheumatic drug as a background therapy
Study NCT00710736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Description: multiple dose, escalating
Study NCT00710736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, 5-fluorouracil prodrug; oral
Description: multiple dose, single schedule
Study NCT03700580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel treatment
Description: Hydrogel dressing containing water, carboxymethyl cellulose and sodium alginate in non-specified proportions, purchased in bulk amounts was sterile dispensed in smaller amounts (200 g) for frequent use.
Study NCT03700580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1G10
Description: P1G10 containing dressing composed by 8% Polawax, 6% liquid vaseline, 0.06% butylated hydroxytoluene, 0.15% Nipagin, 5% propyleneglycol, 0.1% Nipazol, 0.1% ethylenediaminetetraacetate disodium salt, 0.03% methyl-aminopropanol-95, 0.3% Imidazolidinyl urea, 2% Cyclomethicone, 78.2% distilled water. A single batch of the formulation was made and used throughout the intervention. A sample of this preparation was used to assess the extended stability of the formulation. The formulation was dispensed into 100 g dispensers for weekly use.
Study NCT01677156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CORUS CAD (ASGES)
Description: Age/Sex/Gene Expression Score - ASGES
Study NCT03517787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES+TE
Description: Group receive FES+therapeutic exercise during 6 weeks (twice a week). Altogether 8 exercises are conducted, each done 3 sets and 12 repetitions during first three weeks and 4 sets during last three weeks of intervention).
Study NCT03517787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TE
Description: Group perform only therapeutic exercise. Exercises are the same between all 4 groups.
Study NCT03517787 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: REF-FES+TE
Description: Group perform FES+TE, but only participate in 1 session to collect reference data.
Study NCT03517787 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: REF-TE
Description: Group perform only therapeutic exercise, but only participate in 1 session to collect reference data.
Study NCT00121784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1
Study NCT02663050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping
Description: Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
Study NCT02663050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
Study NCT02663050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID's
Description: twice a daily
Study NCT02090413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Study NCT02090413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: enteric-coated capsule
Study NCT02090413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA-Placebo
Description: matched placebo
Study NCT00789880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Administration of oral vitamin D3 at 4000IU
Study NCT00789880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of oral Vitamin D3 placebo
Study NCT00445705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Part A: Placebo every 12 hours for 4 weeks
Study NCT00445705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: AGN 203818 3 mg every 12 hours for 4 weeks
Study NCT00445705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: AGN 203818 20 mg every 12 hours for 4 weeks
Study NCT00445705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: AGN 203818 60 mg every 12 hours for 4 weeks
Study NCT05269342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led counseling and after intervention
Description: the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC
Study NCT02717884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranylcypromine
Description: TCP p.o., daily either 20, 40\*\*, 60\*\*, 80\*\* mg/day, (28d/cycle)~\*\*TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)
Study NCT02717884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Description: 45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
Study NCT02717884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 40mg s.c. (days 1-10)
Study NCT00217243 — intervention group
Intervention type: OTHER
Intervention: Evoked fields before and after a local block (Xylocaine)
Description: MEG registration after electrical median and ulnar nerve stimulation in subjects and patients. In the patient group another MEG was performed after an anaesthetic block (1-2 ml Lidocaine 1%) at the site of the nerve injury producing a painfree state
Study NCT02281357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab dose
Study NCT02281357 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose
Study NCT02046096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Günther Tulip® Vena Cava Filter
Description: Temporary or permanent filter placement for the prevention of pulmonary embolism
Study NCT02046096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Celect® Vena Cava Filters
Description: Temporary or permanent filter placement for the prevention of pulmonary embolism
Study NCT02218242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Description: Intraoperative ultrasound will be performed at the completion of the standard lung cancer resection with mediastinal lymph node dissection. This evaluation will be performed by a different surgeon from the primary surgeon performing the operation to minimize operator variability with the ultrasound system and help control for bias. Additional lymph nodes identified will be resected and sent for pathologic evaluation. It is anticipated that this additional evaluation and treatment should take no more than 30 minutes and as such a time limit of 30 minutes from introduction of the ultrasound probe into the surgical field will be set.
Study NCT04960540 — intervention group
Intervention type: OTHER
Intervention: MRI,
Description: In this project, multi-modal brain imaging methods, such as resting-state functional MRI, task-state functional MRI, structural MRI and diffusion tensor imaging, will be used to analyze brain structure, gray matter morphology, white matter fibrous brain functional activation mode and brain functional connectivity network, and other dimensions.~In particular, combined with the brain functional activities of ALS patients in the cognitive processing task of language understanding and language use, the brain network damage of ALS patients in motor and executive function was compared, and the neural activities and network mechanism of specific changes in language cognitive processing in ALS patients were investigated. Combined with the clinical neuropsychological behavior evaluation data
Study NCT02741869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy (Ondine: MRSAid™)
Description: Photodisinfection using MRSAid™ for the decolonization of S. aureus in hemodialysis patients
Study NCT01640912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXI-109
Description: Single intradermal injection of RXI-109 at incision sites
Study NCT01640912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intradermal injection of placebo at incision sites
Study NCT01753128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipramine
Study NCT01878942 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsules containing mannitol looking identical to LSD~per os
Study NCT01878942 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LSD
Description: 200µg per os, single dose
Study NCT03506737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise protocol
Description: Breathing exercises and global active exercises of the upper and lower limbs while in the upright seated position
Study NCT03506737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise protocol
Description: Stationary cycle ergometer exercise while in the upright seated position for 20 minutes. The protocol will be performed intermittently with 5 periods; each period consists of 3 minutes of cycling followed by 1-minute of rest.
Study NCT03043521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexlansoprazole 60 MG
Study NCT03043521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg
Study NCT03043521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg
Study NCT03043521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 200mg
Study NCT02743884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Warming
Description: 30 minutes of warming from circulating water at about 42 degrees C through an esophageal heat exchanger.
Study NCT02743884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Cooling
Description: 30 minutes of cooling from circulating water at about 7 degrees C through an esophageal heat exchanger.
Study NCT02478970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Konan SP4000
Description: current standard of care at Kellogg Eye Center
Study NCT02478970 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Konan SP4000
Description: current standard of care at Kellogg Eye Center
Study NCT02478970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIDEK CEM-350
Description: newly marketed device
Study NCT02478970 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NIDEK CEM-350
Description: newly marketed device
Study NCT02957591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx®
Description: Streptococcus thermophilus Bifidobacterium breve Bifidobacterium longum Bifidobacterium infantis Lactobacillus acidophilus Lactobacillus plantarum Lactobacillus paracasei Lactobacillus delbrueckii subsp. bulgaricus
Study NCT02957591 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the placebo group will receive a placebo that contains starch but no bacteria. The appearance of the placebo will be indistinguishable in color, shape, size, packaging, smell, and taste from that of the probiotic supplement.
Study NCT04221698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait retraining
Description: 5 gait retraining sessions of continuous feedback in real time during running sessions; using videotape feedback, a digital metronome to increase step rate, and verbal feedback to reduce the tendency to heel strike upon ground contact. Verbal feedback is offered during the 25- to 30-minute running sessions following a series of drills aimed at improving running mechanics.
Study NCT02703415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: caudal block with bupivacaine (0.25%) 1mg/kg
Study NCT02703415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: caudal block with tramadol 1 mg/kg
Study NCT01591967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activator IV Adjusting Instrument
Description: Activator (http://www.activator.com/products-page/) adjustment effects on BP and PR
Study NCT02704338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regulatory T cells
Description: Regulatory t cells will be injected back to autoimmune hepatitis patients
Study NCT00517751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-STOP PEEK
Description: Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
Study NCT00314353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg IV Day 1 every 21 days for eight cycles\*~\*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression.
Study NCT00314353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 IV Day 1 every 21 days for eight cycles
Study NCT00314353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*#~\*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID
Study NCT00314353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 200 mg/m2 IV Day 1 every 21 days for eight cycles
Study NCT02710136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycerinated German Cockroach Allergenic Extract
Description: Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).~Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data).
Study NCT03276312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product
Study NCT04416399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide dry powder inhaler
Description: Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
Study NCT04634396 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACT Acceptance and Commitment Therapy
Description: 6 weeks of 1 hour sessions with a masters prepared research specialist to deliver validated tools
Study NCT06735274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral Autoregulation (CAR)
Description: Cerebral Autoregulation (CAR) is the mechanism capable of maintaining cerebral blood flow constant despite fluctuations in blood pressure. The evaluation of dynamic CAR (dCAR) with spontaneous blood pressure variations allows it to be applied in acute and non-collaborating patients
Study NCT06735274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurovascular coupling (NVC)
Description: Neurovascular coupling (NVC) is the relationship between neural activity and cerebral blood flow, allowing this activity to be evaluated in spatiotemporal terms .
Study NCT06735274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microembolic signals (MES)
Description: Microembolic signals (MES)
Study NCT06735274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment (MoCA)
Description: Montreal Cognitive Assessment (MoCA)
Study NCT06735274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
Description: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
Study NCT06735274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Instrumental Activities of Daily Living Scale (IADL)
Description: Instrumental Activities of Daily Living Scale (IADL)
Study NCT06735274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Rankin Scale for Neurologic Disability (mRS)
Description: Modified Rankin Scale for Neurologic Disability (mRS)
Study NCT04786457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Description: one subcutaneous injection of Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) at 0.5 mL of 6.5 x 10\^3 PFU/mL
Study NCT03188562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Positron Emission Tomography (PET/CT)
Study NCT03188562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA, EUS-NA
Description: Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA) Transbronchial ultrasound examination allow to access upper and lower right paratracheal nodes (2R, 4R), subcarinal (7), hilar and interlobar (10, 11), transesophageal ultrasound examination allow to visualize upper and lower left paratracheal nodes (2L, 4L), subaortic (5), para-aortic (6), subcarinal (7), paraesophageal (8), pulmonary ligament (9) nodes. Furthermore EUS allow to localize mediastinal structures including heart, big vessels, main bronchi, vertebral column and diaphragm and can be used in for visualization of tumor infiltration of surrounding structures especially aorta, pulmonary artery or left atrium.
Study NCT03188562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEMLA
Description: Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) is minimally invasive surgical technique enabling extensive bilateral lymphadenectomy. The procedure starts from 5-8 cm collar incision in the neck, sternum is elevated with a hook connected to a Rochard frame, both laryngeal recurrent nerves and vagus nerves are visualized. During TEMLA all mediastinal nodal stations except for the pulmonary ligament nodes (9) are removed.
Study NCT02430350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Edaravone Injection
Study NCT02430350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edaravone Injection
Study NCT01475604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ivivi Torino II
Description: Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
Study NCT01475604 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ivivi Torino II
Description: Sham treatment for 4 weeks post-surgery
Study NCT02113579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Mouth Rinse 12027-033
Description: After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
Study NCT02113579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mouth Rinse
Description: After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.